Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 6/20 | 0.33 |
| ▸ | HTR2C | P28335 | 6/20 | 0.33 |
| ▸ | HTR2B | P41595 | 5/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21742716 | 1.00 | KCNA3 (0.34) | KCNA3HTR2AHTR2CHTR2BSLC6A2 | |
| SCHEMBL23521674 | 0.80 | SLC6A2 (0.50) | HTR2AHTR2CHTR2BSLC6A2SLC6A4 | |
| SCHEMBL21742882 | 0.80 | SLC6A2 (0.50) | HTR2AHTR2CHTR2BSLC6A2SLC6A4 | |
| SCHEMBL30788068 | 0.80 | SLC6A2 (0.50) | HTR2AHTR2CHTR2BSLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL6712642 | 0.66 | SLC6A4 (0.65) | HTR2AHTR2CHTR2BSLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL6712640 | 0.66 | SLC6A4 (0.65) | HTR2AHTR2CHTR2BSLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL5869202 | 0.66 | SLC6A4 (0.65) | HTR2AHTR2CHTR2BSLC6A2SLC6A4 | |
| SCHEMBL3791653 | 0.65 | KCNA3 (0.47) | KCNA3HTR2AHTR2CHTR2BSLC6A2 | |
| SCHEMBL6267824 | 0.64 | KCNA3 (0.49) | KCNA3HTR2AHTR2CHTR2BSLC6A2 | |
| SCHEMBL5079373 | 0.64 | SLC6A4 (0.56) | SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020035070-A1 | 3-ARYLOXY-3-ARYL-PROPYLAMINE COMPOUND AND USES THEREOF | 漳州片仔癀药业股份有限公司 | 2020-02-20 | — | — | WO | disclosed |